Yahoo Suche Web Suche

Anmelden

Suchergebnisse

  1. Suchergebnisse:

  1. www.antarespharma.comHome :: Antares Pharma

    Antares Pharma is a biopharmaceutical company that develops and commercializes products for the treatment of cancer and other diseases. As of May 24, 2022, it has been acquired by Halozyme, a leading drug delivery business, creating a leading drug delivery business with broadly licensable opportunities across the ENHANZE® and Antares’ auto injector technologies.

    • About Antares

      About Antares. Antares Pharma is a specialty pharmaceutical...

    • Medicines

      Antares Pharma Drug Portfolio. Antares Pharma focuses on the...

    • For Partners

      Partnering with Antares Pharma. Antares Pharma actively...

    • For Investors

      Halozyme has completed its acquistion of Antares Pharma,...

    • For Patients

      Antares strives to be recognized by patients as an...

    • Pipeline

      This site ©2024 Antares Pharma. All Rights Reserved. About...

    • Scientific Publications

      Travanty M 1, Calawa B 2, Shalaby W 3, Jozwiakowski M 3,...

    • Drug Safety

      At Antares Pharma, patient safety is exceptionally important...

  2. www.prnewswire.com › news-releases › halozyme-to-acquireHalozyme to Acquire Antares Pharma to Create a Specialty Product...

    13. Apr. 2022 · Halozyme and Antares Pharma announced a definitive agreement to merge, creating a leading drug delivery and specialty product company. The transaction is expected to be immediately accretive to revenue and non-GAAP earnings in 2022 and to accelerate growth through 2027. The transaction values Antares at $960 million and includes a best-in-class auto injector platform with broad licensing potential.

  3. Videos

    Alle anzeigen

  4. www.pharmaceutical-technology.com › news › halozyme-acquireHalozyme signs agreement to acquire Antares Pharma for $960m

    14. Apr. 2022 · Halozyme Therapeutics has signed a definitive agreement to buy Antares Pharma, a speciality pharmaceutical firm that develops pharmaceutical products and technologies for targeted therapies. The deal will result in the business combination of Halozyme and Antares to create a drug delivery and speciality product company.

    • Vishnu Priyan

  5. www.prnewswire.com › news-releases › halozyme-completesHalozyme Completes Antares Pharma Acquisition - PR Newswire

    24. Mai 2022 · Halozyme, a biopharmaceutical company, completed its acquisition of Antares Pharma, a biotech company that develops and commercializes injectable drugs and fluids. The merger was completed on May 24, 2022, and Antares ceased to be traded on the NASDAQ Global Select Stock Market. The companies have a history of collaborating on products for various indications and markets.

  6. www.reuters.com › business › halozyme-buy-antares-pharma-960Halozyme bolsters drug delivery business with $960 mln Antares...

    13. Apr. 2022 · April 13 (Reuters) - Halozyme Therapeutics Inc (HALO.O) is bolstering its drug delivery platform with a $960 million all-cash deal for specialty pharmaceutical company Antares Pharma Inc...

  7. www.wsj.com › articles › halozyme-therapeutics-nears-deal-toHalozyme Therapeutics Agrees to Buy Antares Pharma - WSJ

    13. Apr. 2022 · Photo: Michael Nagle/Bloomberg News. HALO 2.15% Halozyme Therapeutics Inc. HALO 2.15% agreed to a nearly $1 billion deal to buy specialty pharmaceutical company Antares Pharma Inc. in a move that ...

  8. finance.yahoo.com › news › antares-pharma-announces-fdaAntares Pharma Announces FDA Approval Of TLANDO™, an Oral...

    29. März 2022 · Antares Pharma, a specialty pharmaceutical company, announced that the FDA granted final approval for TLANDO, an oral formulation of testosterone for TRT in adult males. The company expects to launch TLANDO commercially in 2Q 2022 and to leverage its relationships with urologists and endocrinologists.